We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Testing > Content Piece

Colorado Regulator Issues Three Warnings About Moldy Cannabis Products

By Leo Bear-McGuinness

Published: Apr 14, 2023   
A close-up shot of a cannabis bud.

Image credit: iStock

Listen with
Speechify
0:00
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

State regulators in Colorado have once again issued health and safety notices after “potentially unsafe levels” of total yeast and mold, Aspergillus, and heavy metals were found in certain batches of cannabis flower and other products.

The Colorado Department of Revenue (DOR) issued three notices on April 12 concerning three companies.

BBM Enterprises, LLC, reportedly produced flower, shake, trim and pre-rolls contaminated with total yeast and mold, Aspergillus, cadmium, and arsenic.

BBM was also found to have produced batches that had not been submitted for testing and, in certain cases, were initially tested and confirmed to contain levels of contaminants above the acceptable limits for mold and elemental impurities.

These contaminated products were sold at 19 dispensaries throughout Colorado.

Trinidad Cultivation Services reportedly produced flower contaminated with total yeast and mold and Aspergillus. According to the DOR, Trinidad’s flower had initially passed contaminant testing, but subsequently failed retesting.

The products were sold to patients and consumers between October 26, 2022, and March 21, 2023.

COS Investments LLC was also found to have produced flower with worrying levels of Aspergillus. Through an investigation, the DOR determined that one harvest batch belonging to COS Investments wasn’t tested for contaminants prior to being transferred to stores and then failed the DOR’s testing for Aspergillus.

Products from this contaminated batch were sold to patients between February 2 and March 2, 2023.

Any consumers who experience adverse health effects from the products have been advised to seek medical attention immediately and report the event to the Marijuana Enforcement Division (MED) by submitting a MED Reporting Form.

Further information on how to identify affected products can be found here.

 

Like what you just read? You can find similar content on the topic tags shown below.

Policy Testing

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement